Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 12, 2002, Pages 17-21

  Green, Mark R ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IRINOTECAN; NAVELBINE; PLATINUM;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

EID: 0036334217     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)90003-5     Document Type: Review

References (22)

1. A prospective randomized trial of docetaxel (Taxotere) versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
2. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with a platinum containing agent
3. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer
4. A multicenter, randomized phase III study of docetaxel plus best supportive care in chemotherapy-naive patients with metastatic or non-resectable non-small cell lung cancer (NSCLC)
5. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer
6. Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung cancer: A Minnie Pearl Cancer Research Network phase II trial
7. Weekly docetaxel/gemcitabine in the treatment of elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): A Minnie pearl Cancer Research Network phase II trial
8. Challenging the platinum combinations: Docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer
9. A randomized phase III trial of four chemotherapy regimens in advanced NSCLC
10. A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCb) vs. vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer
11. Docetaxel and gemcitabine combinations in non-small cell lung cancer
12. Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor
13. Frontline treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial
14. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial
15. Randomized phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plus irinotecan in advanced non-small-cell lung cancer (NSCLQ: A West Japan Thoracic Oncotogy Group (WJTOG) study
16. Randomized phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plus irinotecan in advanced non-small cell lung cancer (NSCLC): A West Japan Thoracic Oncology Group (WJTOG) study
17. Weekly chemotherapy (CT) with carboplatin (CBDCA), docetaxel (DOC) and irinotecan (CPT-11) in advanced non-small-cell lung cancer (NSCLC). A phase II study
18. Pathological stage IIIb non-small cell lung cancer (NSCLC): Prolonged survival with consolidation of docetaxel following concurrent chemoradiotherapy (SWOG 9504)
19. Clinical studies of docetaxel (Taxotere) and concomitant chest therapy
20. Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-smalI-cell lung carcinoma
21. Combining taxanes with radiation for solid tumors
22. Phase I trial of outpatients weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small cell lung cancer. A Vanderbilt Cancer Center Affiliation Network (VCCAN) trial